The Impact of Reducing Hypertensive Left Ventricular Hypertrophy on Sudden Cardiac Death
AbstractIt has been well recognized that the presence of left ventricular hypertrophy (LVH) is an adverse feature in hypertension, with such patients having a substantially higher risk of cardiovascular events, including mortality and morbidity from heart failure, ventricular arrhythmias, death from myocardial infarction, sudden cardiac death and cerebrovascular episodes. ECG may show findings suggestive of hypertrophy but echocardiography is the preferred test for the evaluation of the presence and extent of hypertrophy. The reduction of blood pressure via life style interventions and with the use of antihypertensive agents reduces cardiac mass in patients with LVH. This reduction is related both to the degree of antihypertensive response and to the specific therapy used. It appears that the degree of regression is more pronounced with angiotensin-converting enzyme inhibitors and calcium channel blockers, especially non-dihydropyridines. The regression of LVH is accompanied by a reduction in sudden death, acute myocardial infarction and heart failure.
a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).